Carmen Palomino-Cano

Mrs. Carmen Palomino-Cano

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Socorro EspuelasSocorro Espuelas
Socorro Espuelas
CPCarmen Palomino-Cano
Carmen Palomino-Cano
CSCarlos Torrado Salmerón
Carlos Torrado Salmerón
HSHelga Karina Ruiz Saldaña
Helga Karina Ruiz Saldaña
Paloma Marina de la Torre-IglesiasPaloma Marina de la Torre-Iglesias
Paloma Marina de la Torre-Iglesias
Javier CarriónJavier Carrión
Javier Carrión
Cutaneous leishmaniosis (CL) remains a major neglected tropical disease, with current therapies constrained by toxicity, high cost, and variable efficacy. Here, we evaluated an immunochemotherapy strategy combining topical amphotericin B (AmB) with the therapeutic DNA vaccine HisAK70 in a murine model of Leishmania major infection. BALB/c mice were subcutaneously infected and treated with topical AmB cream alone, AmB plus HisAK70, or paromomycin (PM) as a reference therapy. Therapeutic efficacy was assessed through lesion progression, parasite burden in draining lymph nodes and spleen, and immunological markers associated with parasite control. Both PM and the combined AmB + HisAK70 treatment significantly reduced lesion progression and markedly decreased parasite burden compared with infected controls, demonstrating effective control of local infection and systemic dissemination. Importantly, the combination therapy enhanced the efficacy of AmB alone, supporting the beneficial contribution of vaccine-driven immune modulation to therapeutic outcome. Therapeutic efficacy was associated with reduced arginase activity in infected tissues and an increased IFN-γ/IL-4 ratio, indicative of a protective Th1-oriented immune response. Together, these findings highlight immunochemotherapy as a promising strategy for CL treatment, integrating localized topical drug delivery with targeted immune activation to improve therapeutic efficacy while potentially reducing systemic toxicity.

6 July 2026 in Advanced Healthcare Materials
Verified
Journal Article
Open access
PDF file
CPCarmen Palomino-Cano
Carmen Palomino-Cano
MMM. Carmen Mera‐Delgado
M. Carmen Mera‐Delgado
EMEsther Moreno
Esther Moreno
ELEsther Larrea
Esther Larrea
LALecnia Aguirre
Lecnia Aguirre
Socorro EspuelasSocorro Espuelas
Socorro Espuelas
Cutaneous leishmaniasis (CL) remains difficult to treat because Leishmania parasites persist within dermal macrophages and suppress their microbicidal activity, promoting chronic infection. Toll‐like receptor (TLR) agonists can restore macrophage effector functions, but their therapeutic use is limited by systemic toxicity. Here, we developed a lipid‐based nanoemulsion (NE) for the systemic delivery of the TLR7 agonist gardiquimod (GDQM) to improve macrophage targeting and reduce off‐target inflammatory effects. Following intravenous administration, GDQM‐NEs efficiently accumulated in dermal lesions and significantly reduced systemic cytokine release compared with free GDQM, resulting in an improved safety profile. Importantly, nanoencapsulation preserved GDQM antileishmanial activity achieving an approximately 2‐log reduction in parasite burden. Treatment induced both Th1‐associated cytokines (IFN‐γ and IL‐12p70) and regulatory responses, including IL‐10 production and FoxP3 + regulatory T‐cell expansion. Despite efficient lesion accumulation, CD86 upregulation was detected in macrophages from draining lymph nodes (dLNs) but not at the lesion site, indicating limited local macrophage activation. These findings indicate that GDQM‐NEs effectively overcome major delivery and safety barriers associated with systemic TLR7 agonist administration, whereas the lesion microenvironment and TLR‐driven regulatory mechanisms remain key constraints on therapeutic efficacy. Combining TLR agonists with strategies that counteract these local suppressive pathways may further enhance treatment outcomes in CL.